Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Raloxifene (Evista) vs Zoledronate: Raloxifene (Evista) has the stronger overall evidence (5.3 vs 3/10); they're alternatives for bone health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Raloxifene (Evista) wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
Shared outcomes (1)
Outcomes where both Raloxifene (Evista) and Zoledronate have evidence — compare verdict strength side-by-side.
Approved (postmenopausal women) / off-label (male) — clinician-directed. For osteoporosis treatment/prevention and breast-cancer risk reduction the standard, validated dose is 60 mg once daily (the MORE, CORE, RUTH and STAR trials all used 60 mg/day; MORE also tested 120 mg/day with no clear added fracture benefit and more side effects). For off-label male gynecomastia the small published pediatric series used roughly 60 mg/day; there is no FDA-approved male dose and the male evidence is thin and retrospective.
any
Raloxifene hydrochloride 60 mg tablets (approved for postmenopausal osteoporosis and breast-cancer risk reduction)
Approved osteoporosis dosing is a single 5 mg intravenous infusion once yearly, given by a clinician (with adequate calcium/vitamin D and hydration). There is no validated longevity regimen; off-label geroprotective use would follow the same infusion under medical supervision.
any
Once-yearly intravenous infusion (5 mg)
Months to years
Years
Throughout use
Throughout use
~3 years
Years
First few days after infusion
Variable
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.
JAMA (1999) · Rct · n=7705
MORE: multicenter, randomized, double-blind, placebo-controlled trial of raloxifene 60 or 120 mg/day in 7,705 postmenopausal women with osteoporosis, followed up to 36 months
The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.
JAMA (1999) · Rct · n=7705
Pre-specified breast-cancer analysis of the MORE RCT (7,705 postmenopausal women with osteoporosis), followed a median 40 months
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.
J Natl Cancer Inst (2004) · Rct · n=5213
CORE: extension of the randomized MORE trial giving 4 additional years of raloxifene 60 mg/day (n=3,510) vs continued placebo (n=1,703)
Zoledronic acid and clinical fractures and mortality after hip fracture.
The New England journal of medicine (2007) · Rct · n=1065
HORIZON Recurrent Fracture Trial: zoledronate vs placebo after hip fracture (n=1065)
Bisphosphonates and lifespan.
Bone (2020) · Review
Review of bisphosphonates and lifespan/aging
Fracture prevention in patients with cognitive impairment presenting with a hip fracture: secondary analysis of data from the HORIZON Recurrent Fracture Trial.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2014) · Rct
Randomized fracture-prevention trial in a cognitively impaired hip-fracture population
Raloxifene (Evista) has a higher evidence score (5.3/10 vs 3/10) and wins in 2 of 3 categories.
For bone health, Raloxifene (Evista) has a higher relevance score (76 vs 74).
No known interactions between Raloxifene (Evista) and Zoledronate have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.